Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients
Authors:
Open Access
- 24 August 2024
- journal article
- research article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 41, 100839
Abstract
No abstract availableKeywords
Funding Information
- Ministero della Salute (CO-2016-02361470)
- Ministero della Salute (2022-2024)
This publication has 24 references indexed in Scilit:
- ‘Plasma first’ approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinomaJournal of Cancer Research and Clinical Oncology, 2024
- The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian populationLung Cancer, 2024
- Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsiesBritish Journal of Cancer, 2023
- Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer CenterHeliyon, 2023
- Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)Clinical Lung Cancer, 2022
- Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitorsBritish Journal of Cancer, 2022
- The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practiceCritical Reviews in Oncology/Hematology, 2022
- When Tissue is an Issue the Liquid Biopsy is Nonissue: A ReviewOncology and Therapy, 2021
- Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitorsCancer, 2019
- Liquid biopsy as a follow‐up tool: Comment on longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitorsCancer, 2019